The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma.
 
Matthew J. Frigault
Consulting or Advisory Role - Arcellx; Bristol-Myers Squibb/Juno; Bristol-Myers Squibb/Juno; Foundation Medicine (Inst); Gilead Sciences; Incyte; Novartis
Patents, Royalties, Other Intellectual Property - Own IP related to chimeric antigen receptors and T cell manufacturing
 
Jacalyn Rosenblatt
Employment - Bioclinica; Imaging Endpoints; Parexel; Wolters Kluwer (I)
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Amgen; Attivare Therapeutics; BMS; Celgene; Karyopharm Therapeutics; Kite/Gilead; Partner Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Sanofi (Inst)
Other Relationship - Dava Oncology
 
Daniella Cook
Travel, Accommodations, Expenses - Adaptimmune
 
Ha Na Cho
No Relationships to Disclose
 
Gabriel D. Depinho
No Relationships to Disclose
 
Emma Logan
No Relationships to Disclose
 
Jessica Liegel
No Relationships to Disclose
 
Yougeesh Prabhakar
No Relationships to Disclose
 
Christine Cornwell
Employment - Arcellx
Stock and Other Ownership Interests - Arcellx
 
Kamalika Banerjee
Employment - Arcellx
 
Anand Rotte
Employment - Arcellx
 
Christopher Ryan Heery
Employment - Arcellx
Leadership - Arcellx
Stock and Other Ownership Interests - Arcellx
Research Funding - Arcellx
Travel, Accommodations, Expenses - Arcellx
 
David Avigan
Employment - Parexel
Consulting or Advisory Role - Aviv MedTech; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite/Gilead; Legend Biotech; Partner Therapeutics; Sanofi; Takeda; Takeda
Research Funding - Celgene; Kite, a Gilead company; Pharmacyclics
 
Andrzej J. Jakubowiak
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Gracell; Janssen; Karyopharm Therapeutics; Sanofi
 
Michael Russell Bishop
Honoraria - Bristol-Myers Squibb/Celgene/Juno; Incyte; Incyte; Sanofi/Aventis
Consulting or Advisory Role - Arcellx; Autolus; BMS; crispr therapeutics; Iovance Biotherapeutics; Kite, a Gilead company; Novartis; Sana Biotechnology
Speakers' Bureau - Agios; Bristol-Myers Squibb; Incyte; Kite, a Gilead company; Sanofi
Research Funding - Arcellx (Inst); crispr therapeutics (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Expert Testimony - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - BMS; Kite/Gilead; Novartis